Investing.com - AstraZeneca ADR (NASDAQ: AZN) reported third quarter EPS of $1.73, $0.87 better than the analyst estimate of $0.86. Revenue for the quarter came in at $11.49B versus the consensus estimate of $11.54B.
AstraZeneca ADR's stock price closed at $63.53. It is down -9.72% in the last 3 months and down -2.40% in the last 12 months.
AstraZeneca ADR saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See AstraZeneca ADR's stock price’s past reactions to earnings here.
According to InvestingPro, AstraZeneca ADR's Financial Health score is "great performance".
Check out AstraZeneca ADR's recent earnings performance, and AstraZeneca ADR's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in AZN right now?
With AZN making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed AZN alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including AZN, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is AZN poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now